---
figid: PMC5992820__13058_2018_983_Fig1_HTML
figlink: /pmc/articles/PMC5992820/figure/Fig1/
number: F1
caption: Simplified schematic diagram of the pathways described in this study. a Growth
  factor signalling (IGFR and ERBB) leads to activation of PI3K and phosphorylation
  of AKT. AKT inhibits TCS1/2, resulting in upregulation of mTORC1. In parallel, mTORC1
  can also be upregulated by the RAS-RAF-MEK-ERK signalling pathway. ERK phosphorylates
  and inactivates TCS2 also leading to mTORC1 activation. S6 K1 activity increases
  as a result of mTORC1 activation. S6 K1 suppresses mTORC2 and IRS1. ER is also a
  target of S6 K1 leading to phosphorylation of serine 167. b Inhibition of mTORC1
  with everolimus suppresses S6 K1 removing the negative feedback loop causing a rise
  in IRS1 and AKT activity via loss of suppression on mTORC2. Increased AKT activity
  suppresses TCS1/2 and increases expression of growth factor receptors (ERBB2/3)
  enhancing RAS-RAF-ERK signalling. c The dual blockade of ERBBs (neratinib) and mTORC1
  signalling (everolimus) may suppress the two feedback loops described in b. Yellow
  shows normal mTORC signalling cascade; blue represents activated proteins; red represents
  inhibited proteins; dotted lines show loss of normal feedback loops
pmcid: PMC5992820
papertitle: Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth
  factor, and oestrogen receptor signalling pathways in endocrine-resistant breast
  cancer.
reftext: Ricardo Ribas, et al. Breast Cancer Res. 2018;20:44.
pmc_ranked_result_index: '14737'
pathway_score: 0.8999083
filename: 13058_2018_983_Fig1_HTML.jpg
figtitle: Simplified schematic diagram of the pathways described in this study
year: '2018'
organisms:
- Mus musculus
- Armoracia rusticana
- Olea europaea
- Homo sapiens
- Bos taurus
- Oryctolagus cuniculus
ndex: f4ee1e43-df13-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5992820__13058_2018_983_Fig1_HTML.html
  '@type': Dataset
  description: Simplified schematic diagram of the pathways described in this study.
    a Growth factor signalling (IGFR and ERBB) leads to activation of PI3K and phosphorylation
    of AKT. AKT inhibits TCS1/2, resulting in upregulation of mTORC1. In parallel,
    mTORC1 can also be upregulated by the RAS-RAF-MEK-ERK signalling pathway. ERK
    phosphorylates and inactivates TCS2 also leading to mTORC1 activation. S6 K1 activity
    increases as a result of mTORC1 activation. S6 K1 suppresses mTORC2 and IRS1.
    ER is also a target of S6 K1 leading to phosphorylation of serine 167. b Inhibition
    of mTORC1 with everolimus suppresses S6 K1 removing the negative feedback loop
    causing a rise in IRS1 and AKT activity via loss of suppression on mTORC2. Increased
    AKT activity suppresses TCS1/2 and increases expression of growth factor receptors
    (ERBB2/3) enhancing RAS-RAF-ERK signalling. c The dual blockade of ERBBs (neratinib)
    and mTORC1 signalling (everolimus) may suppress the two feedback loops described
    in b. Yellow shows normal mTORC signalling cascade; blue represents activated
    proteins; red represents inhibited proteins; dotted lines show loss of normal
    feedback loops
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3R3
  - IGF1R
  - MAP2K1
  - PIK3R4
  - PIK3CA
  - PIK3CG
  - AKT3
  - RAF1
  - IRS1
  - ARAF
  - BRAF
  - MAPK1
  - PDK1
  - PIK3R6
  - PIK3R5
  - TSC2
  - TSC1
  - PIK3CB
  - PIK3CD
  - RPTOR
  - AKT1
  - AKT2
  - ERBB2
  - ERBB3
  - MAPK3
  - MAPKAP1
  - HRAS
  - NRAS
  - RPS6KB1
  - MLST8
  - MAP2K2
  - MTOR
  - RICTOR
  - KRAS
  - Neratinib
  - Everolimus
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: IGF1R
  symbol: IGF1R
  source: hgnc_symbol
  hgnc_symbol: IGF1R
  entrez: '3480'
- word: MEK1/2
  symbol: MEK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: IRS1
  symbol: IRS1
  source: hgnc_symbol
  hgnc_symbol: IRS1
  entrez: '3667'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: ERK1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: PDK1
  symbol: PDK1
  source: hgnc_symbol
  hgnc_symbol: PDK1
  entrez: '5163'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: TSC1/2
  symbol: TSC2
  source: hgnc_symbol
  hgnc_symbol: TSC2
  entrez: '7249'
- word: TSC1/2Everolimus
  symbol: TSC1
  source: hgnc_symbol
  hgnc_symbol: TSC1
  entrez: '7248'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: MTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: RPTOR
  entrez: '57521'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: ERBB2/3
  symbol: ERBB2
  source: hgnc_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: ERBB2/3
  symbol: ERBB3
  source: hgnc_symbol
  hgnc_symbol: ERBB3
  entrez: '2065'
- word: ERK1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MAPKAP1
  entrez: '79109'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: S6K1
  symbol: S6K1
  source: hgnc_alias_symbol
  hgnc_symbol: RPS6KB1
  entrez: '6198'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MLST8
  entrez: '64223'
- word: MEK1/2
  symbol: MEK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: RICTOR
  entrez: '253260'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
chemicals:
- word: Neratinib
  source: MESH
  identifier: C487932
- word: Everolimus
  source: MESH
  identifier: C107135
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC5992820__F1
redirect_from: /figures/PMC5992820__F1
figtype: Figure
---
